Dr. Helen Lee
Helen Lee received her master’s and PhD from University of Oxford and Cornell University respectively. She is a researcher/entrepreneur with a lifelong dedication to medical diagnostics. She withdrew from a successful career in industry at Abbott Laboratories, Chicago as head of Molecular Diagnostics Business Unit, to focus on the pursuit of advanced technologies specifically suited for resource-strapped regions. After creating the Diagnostics Development Unit at Cambridge University, Dr Lee founded — together with a group of like-minded colleagues — a spinout company called Diagnostics for the Real World Ltd, with the single purposes of delivering much-needed high performance yet simple and robust molecular tests to the developing world. She chaired the Diagnostic Steering Committee at the World Health Organization and among the many awards received, she is the recipient of the prestigious Lord Lloyd Kilgerran Award, the British Female Inventor in Industry Award, the European Women of Achievement Award and the Asian Women of Achievement Award. In 2016, she was a winner of the European Inventor’s award.
Dr. Benjamin Chen
Dr. Benjamin Chen is a scientist, entrepreneur and investor with strong merchant banking acumen. He is currently a Venture Partner with Panacea Venture, a global life science venture fund. Most recently he served as the CEO of ImaginAb, Inc. developing a cutting edge platform to address an urgent unmet need in immuno-oncology. Immediately before that, he was the Chairman and CEO of London based Immune Targeting Systems, Inc. He has spent nine years as a Managing Director at Burrill & Company, a global life sciences venture firm where he evaluated investment opportunities, assisted a global clientele in completing licensing, partnering and M&A transactions. He also played a key role in establishing the Malaysian Life Sciences Fund. Earlier in his career as an R&D executive, he has experience in building talented research team in immunology, stem cell biology, genomics, gene therapy and molecular diagnostics in both biotechnology start-ups and multinational pharmaceutical companies including Roche Diagnostics and Novartis. Dr. Chen received his academic training in Microbiology and Immunology at the University of Wisconsin-Madison and Stanford University.
Guido has over 30 years of experience with major health care and diagnostic companies in sales, marketing, manufacturing and business development. Companies include Johnson and Johnson in senior sales management, Abbott Diagnostics in both marketing, and country management, Murex Diagnostics as Director of Commercial operations. In addition, he has assisted various startups with their funding activities including an initial public offering for a Norwegian diagnostic startup.
Dr. David Owen
Over 20 years of R&D experience in the pharmaceutical industry and inventor of a marketed drug. Founding CEO, Medical Research Council Technology Ltd (UK). Served on Government Committees in many countries and a United Nations Development Programme. Also, a non-executive Director, Oxford Gene Technology Ltd.: Cardiff Scintigraphics Ltd. and the Supervisory Board, European Molecular Biology Laboratory Technology Transfer company EMBLEM and on the Investment Committee at the linked Venture Capital Fund.
Ms. Sylvia Chiou served as Chief of Staff Unit of Wistron Corporation and has accumulated over 15 years of investment management experience. In addition to that, she also served as the company secretary to implement and enhance the standards of corporate governance in Wistron. Ms. Sylvia Chiou obtained her Bachelor Degree in Economics from National Taiwan University and a Master of Business Administration Degree from University of Pittsburgh.